Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma

Correlation between Serum Tumor Markers and Efficacy of First-line EGFR-TKIs in Patients with Advanced Lung Adenocarcinoma

Background and objective Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) significantly improve the survival of advanced lung adenocarcinoma patients harboring EGFR mutation. Limited to the standards of tumor tissue samples and detection methods, still some people can’t receiv...

Full description

Bibliographic Details
Main Authors:	Hanxiao CHEN, Xue YANG, Huijun LIU, Kun MA, Jia ZHONG, Zhi DONG, Minglei ZHUO, Yuyan WANG, Jianjie LI, Tongtong AN, Meina WU, Ziping WANG, Jun ZHAO
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2017-09-01
Series:	Chinese Journal of Lung Cancer
Subjects:	Serum tumor markers Lung neoplasms EGFR-TKIs Efficacy Survival
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2017.09.01

Similar Items

Role of the Expression Level of Nrf2 in Predicting Response of EGFR-TKIs  in Lung Adenocarcinoma Patients with EGFR Gene Mutations
by: Xiang ZHU, et al.
Published: (2014-02-01)

Prognostic Factors in Lung Adenocarcinoma with Bone Metastasis Treated with EGFR-TKIs
by: Tzu-Hsuan Chiu, et al.
Published: (2021-09-01)

Effects of EGFR Gene Polymorphisms on Efficacy and Prognosis  in Advanced Non-small Cell Lung Cancer Treated with EGFR-TKIs
by: Liangshan DA, et al.
Published: (2013-03-01)

Research Progress of the Resistance Mechanism of Non-small Cell Lung Cancer  to EGFR-TKIs
by: Huihui LIU, et al.
Published: (2013-10-01)

Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
by: Yanxin Chen, et al.
Published: (2019-08-01)

ΔCT Value of Amplified Refractory Mutation System Predicts Efficacy of EGFR-TKIs in Advanced Non–Small-Cell Lung Cancer: A Multi-Center Retrospective Study
by: Min Chen, et al.
Published: (2021-10-01)

Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer
by: Yu X, et al.
Published: (2021-05-01)

Treatment Choice for Advanced Non-small Cell Lung Cancer Patients Who Had Gradual Progression After EGFR-TKIs: 32 Cases Report
by: Lin LIN, et al.
Published: (2013-10-01)

The Predictive Value of EGFR Status in Non-small Cell Lung Cancer Patients Treated with EGFR-TKIs
by: Jun CHEN, et al.
Published: (2010-04-01)

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
by: In Ae Kim, et al.
Published: (2018-07-01)

Advanced Research on MicroRNAs and EGFR-TKIs Secondary Resistance
by: Ming WANG, et al.
Published: (2015-12-01)

First-Line EGFR-TKIs Treatment in Stage I Non-Small-Cell Lung Cancer Patients Harboring EGFR Gene Mutations with Postoperative Intrapulmonary Recurrence
by: Zhu Z, et al.
Published: (2021-02-01)

EGFR-TKIs resistance via EGFR-independent signaling pathways
by: Qian Liu, et al.
Published: (2018-02-01)

Central nervous system progression in advanced non–small cell lung cancer patients with EGFR mutations in response to first-line treatment with two EGFR-TKIs, gefitinib and erlotinib: a comparative study
by: Meng-Xia Li, et al.
Published: (2017-04-01)

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in <i>EGFR</i>-Mutant Stage III-pN2 Lung Adenocarcinoma
by: Qiwen Li, et al.
Published: (2021-04-01)

Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer
by: Yingying Pan, et al.
Published: (2019-04-01)

Soluble PD-L1 as a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients With EGFR Mutations
by: Yijun Jia, et al.
Published: (2020-08-01)

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
by: Yuan Gao, et al.
Published: (2017-07-01)

Advance in MicroRNAs and EGFR-TKIs Secondary Resistance Research  in Non-small Cell Lung Cancer
by: Xiaoyang DUAN, et al.
Published: (2014-12-01)

Bilirubin Can Be Used as a Prognostic Factor for Lung Adenocarcinoma Patients with EGFR Mutations
by: Geng Y, et al.
Published: (2020-10-01)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
by: Dantong Sun, et al.
Published: (2020-07-01)

Research Progress of the Role of EMT in EGFR-TKIs Resistance  of Non-small Cell Lung Cancer
by: Li YU, et al.
Published: (2018-12-01)

First-generation EGFR tyrosine kinase inhibitor therapy in 106 patients with compound EGFR-mutated lung cancer: a single institution’s clinical practice experience
by: Xiangyang Yu, et al.
Published: (2018-07-01)

Mechanisms of resistance to EGFR tyrosine kinase inhibitors
by: Lihua Huang, et al.
Published: (2015-09-01)

Effectiveness of EGFR-TKIs versus Chemotherapy as First-line Treatment for Advanced Non-small Cell Lung Cancer: A Meta-analysis
by: Feifei CAO, et al.
Published: (2015-03-01)

Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations
by: Wang J, et al.
Published: (2016-06-01)

Research Progress on Resistance Mechanisms and Overcoming Strategies to Third-generation EGFR-TKIs in Advanced Non-small Cell Lung Cancer
by: HE Jingyi, et al.
Published: (2019-10-01)

The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients
by: Anna Maria Rachiglio, et al.
Published: (2019-03-01)

Comparison of Different EGFR Gene Mutation Status in Patients with Metastatic Non-Small Lung Cancer After First-Line EGFR-TKIs Therapy and Analyzing Its Relationship with Efficacy and Prognosis
by: Yuan C, et al.
Published: (2021-09-01)

Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-κB Signaling Pathway
by: Ling Li, et al.
Published: (2020-09-01)

Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients
by: Rui-Lian Chen, et al.
Published: (2021-04-01)

Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma
by: Fangqiu Fu, et al.
Published: (2021-04-01)

Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon <i>EGFR</i> Mutations: Are They Different from Those with Common <i>EGFR</i> Mutations?
by: Hyun Ae Jung, et al.
Published: (2020-10-01)

Concomitant genetic alterations having greater impact on the clinical benefit of EGFR‐TKIs in EGFR‐mutant advanced NSCLC than BIM deletion polymorphism
by: Si‐Yang Liu, et al.
Published: (2020-03-01)

Chemotherapy with or without pemetrexed as second-line regimens for advanced non-small-cell lung cancer patients who have progressed after first-line EGFR TKIs: a systematic review and meta-analysis
by: Li ZH, et al.
Published: (2018-06-01)

Efficacy of the CDK7 Inhibitor on EMT-Associated Resistance to 3rd Generation EGFR-TKIs in Non-Small Cell Lung Cancer Cell Lines
by: Wonjun Ji, et al.
Published: (2020-12-01)

Anti-EGFR therapies in nasopharyngeal carcinoma
by: Xishan Chen, et al.
Published: (2020-11-01)

Vandetanib Treatment in Refractory Advanced Lung Adenocarcinoma Patients:  Five Cases and Review of Literature
by: Lili GUO, et al.
Published: (2012-02-01)

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
by: Tohru Ohmori, et al.
Published: (2021-01-01)

KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma
by: Xu H, et al.
Published: (2020-08-01)